A 52-year-old woman with HER2-positive metastatic breast cancer is being counseled about monoclonal antibody-based targeted therapies. All of the following statements regarding HER2-directed monoclonal antibodies are true EXCEPT:

Question

Accepted Answer

B. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that delivers the microtubule-stabilizing agent paclitaxel directly to HER2-positive cancer cells. ## HER2-Directed Targeted Therapies in Breast Cancer

**Key Point:** HER2-positive breast cancer (overexpression in ~20% of cases) is treated with a combination of monoclonal antibodies, antibody-drug conjugates, and small-molecule TKIs. Each agent has a distinct mechanism and payload.

## Comparison of HER2-Directed Agents

| Agent | Class | Mechanism | Payload/Target | Correct? |
|-------|-------|-----------|----------------|----------|
| Trastuzumab | mAb | Binds HER2 ECD; ADCC + signal inhibition | None (naked antibody) | ✓ |
| Pertuzumab | mAb | Binds HER2; blocks HER2-HER3 dimerization | None (naked antibody) | ✓ |
| T-DM1 | ADC | Trastuzumab backbone + cytotoxic linker | **Mertansine (DM1)** — microtubule destabilizer | ✗ |
| Lapatinib | TKI | ATP-competitive inhibitor | EGFR + HER2 kinase domains | ✓ |

**High-Yield:** T-DM1 (trastuzumab emtansine) delivers **mertansine (DM1)**, a microtubule-**destabilizing** agent (maytansinoid), NOT paclitaxel. Paclitaxel is a microtubule-**stabilizing** agent — a common trap for students.

## Antibody-Drug Conjugate (ADC) Mechanism

1. Trastuzumab binds to HER2 on cancer cell surface
2. Receptor-mediated endocytosis internalizes the antibody-drug complex
3. Lysosomal degradation releases mertansine (DM1) intracellularly
4. DM1 binds to β-tubulin and **destabilizes** microtubules → mitotic arrest → apoptosis

**Clinical Pearl:** The advantage of T-DM1 over free paclitaxel is targeted delivery — the cytotoxic agent is only released inside HER2-positive cells, reducing systemic toxicity and improving the therapeutic window.

## Mechanism Distinction: Microtubule Effects

| Agent | Class | Effect on Microtubules | Clinical Use |
|-------|-------|------------------------|---------------|
| Paclitaxel | Taxane | **Stabilizes** (prevents depolymerization) | Chemotherapy |
| Mertansine (DM1) | Maytansinoid | **Destabilizes** (prevents polymerization) | ADC payload |
| Vinca alkaloids | Alkaloid | Destabilizes | Chemotherapy |

**Warning:** Do not confuse paclitaxel (stabilizer) with mertansine (destabilizer). This is a high-yield distinction in pharmacology exams.

Answer

A. Lapatinib is a small-molecule tyrosine kinase inhibitor that inhibits both EGFR and HER2 and can be used in patients with HER2-positive breast cancer resistant to trastuzumab

Answer

C. Trastuzumab (Herceptin) is a humanized monoclonal antibody that binds to the extracellular domain of HER2 and mediates antibody-dependent cellular cytotoxicity (ADCC) and inhibits HER2 signaling

Answer

D. Pertuzumab is a monoclonal antibody that binds to HER2 and prevents heterodimerization with HER3, thereby blocking ligand-independent signaling pathways

A 52-year-old woman with HER2-positive metastatic breast cancer is being counseled about monoclonal antibody-based targeted therapies. All of the following statements regarding HER2-directed monoclonal antibodies are true EXCEPT:

Explanation

Practice similar questions